4857-01-6

Basic information

• Product Name: 2-(2-Hydroxyethyl)benzimidazole
• Synonyms: 1H-Benzimidazole-2-ethanol(9CI);1H-Benzimidazole-2-ethanol;2-(2-Hydroxyethyl)benzimidazole;2-(1H-benzimidazol-2-yl)ethanol(SALTDATA: FREE);2-(1H-1,3-benzodiazol-2-yl)ethan-1-ol;2-(1H-Benzo[d]iMidazol-2-yl)ethanol;2-(.beta.-Hydroxyethyl)benzimidazole;2-(beta-Hydroxyethyl)benzimidazole
• CAS NO: 4857-01-6
• Molecular Formula: C₉H₁₀N₂O
• Molecular Weight: 162.19
• EINECS: 225-453-3
• Product Categories: BENZIMIDAZOLE
• Mol File: 4857-01-6.mol

Chemical Properties

• Melting Point: 152-154 ºC
• Boiling Point: 428.6±28.0 °C at 760 mmHg
• Flash Point: 213.0±24.0 °C
• Appearance: /
• Density: 1.293
• Vapor Pressure: 4.15E-08mmHg at 25°C
• Refractive Index: 1.685
• PKA: 11.79±0.10(Predicted)
• CAS DataBase Reference: 2-(2-Hydroxyethyl)benzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Hydroxyethyl)benzimidazole(4857-01-6)
• EPA Substance Registry System: 2-(2-Hydroxyethyl)benzimidazole(4857-01-6)

Safety Data

• Hazardous Substances Data: 4857-01-6(Hazardous Substances Data)

Usage

Chemical Properties

White to white powder

InChI:InChI=1/C9H10N2O/c12-6-5-9-10-7-3-1-2-4-8(7)11-9/h1-4,12H,5-6H2,(H,10,11)

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 109-78-4 3-Hydroxypropionitrile 

Downstream Products

• 20224-09-3 1-(1H-benzo[d]imidazol-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one 
• 36998-77-3 1-(1H-benzo[d]imidazol-2-yl)-3-(4-chlorophenyl)prop-2-en-1-one 
• 20224-10-6 1-(1H-benzo[d]imidazol-2-yl)-3-phenylprop-2-en-1-one 
• 34734-29-7 2-(1-methyl-1H-benzo[d]imidazol-2-yl)ethan-1-ol 

Relevant articles and documents

4-Isopropylchroman-3-ol derivatives

The present invention relates to a novel 4-isopropylchroman-3-ol compound, a pharmaceutical composition comprising the novel compound as an effective component, and to an intermediate compound useful for synthesizing the compound. When administered to a patient with a drug causing toxicity, the novel 4-isopropylchroman-3-ol compound exhibits efficacy of reducing toxicity of the drug by reducing antagonism regarding a T-type calcium channel and/or activity of cytochrome P450 isozyme.

Efficient synthesis of mibefradil analogues: An insight into in vitro stability

This article describes the synthesis and biological evaluation of a chemical library of mibefradil analogues to investigate the effect of structural modification on in vitro stability. The construction of the dihydrobenzopyran structure in mibefradil derivatives 2 was achieved through two efficient approaches based on a diastereoselective intermolecular Reformatsky reaction and an intramolecular carbonyl-ene cyclization. In particular, the second strategy through the intramolecular carbonyl-ene reaction led to the formation of a key intermediate 3 in a short and highly stereoselective way, which has allowed for practical and convenient preparation of analogues 2. Using this protocol, we could obtain 22 new mibefradil analogues 2, which were biologically tested for in vitro efficacies against T-type calcium channels and metabolic stabilities. Among the synthesized compounds, we found that analogue 2aa containing a dihydrobenzopyran ring and a secondary amine linker showed high % remaining activities of the tested CYP enzymes retaining the excellent T-type calcium channel blocking activity. These findings indicated that the structural modification of 1 was effective for improving in vitro stability, i.e., reducing CYP inhibition and metabolic degradation. the Partner Organisations 2014.

Synthesis, cytotoxicity, and DNA interactions of new cisplatin analogues containing substituted benzimidazole ligands

Six new platinum(II) complexes with 1-H or methyl-2-chloromethyl or acetoxymethyl or 2′-hydroxyethyl- benzimidazole carrier ligands were synthesized and evaluated for their reactivity against model nucleophile I -, cellular uptake, and in vitro antiproliferative activities against the human MCF-7 breast and HeLa cervix cancer cell lines. The effect of the compounds on pBR322 plasmid DNA was studied by gel electrophoretic mobility measurements. Flow cytometric analysis was also carried out to study the effect of representative compounds 1 and 2, bearing 2-chloromethyl or -acetoxymethylbenzimidazole carrier ligands, on the cell cycle distribution of MCF-7 and HeLa cells, respectively. In general, it was found that Pt(II) complexes were less cytotoxic than cisplatin and were comparable to carboplatin. The results of the plasmid DNA interaction and the restriction studies suggest that changing the chemical structure of the benzimidazole ligands may modulate DNA binding mode and the sequence selectivity. Compounds 1 and 2 had no significant effect on the cell cycle profile of the cells used. However, compound 2 induced a significant increase in the SubG1 cell population at a concentration of 20 μM.